Menopausal estrogens and breast cancer.
1891 women given conjugated estrogens for the menopause were followed for 12 years (mean) for incidence of breast cancer. Overall, 49 cases were observed; 39.1 were expected on the basis of rates in the general population (relative risk = 1.3, P = 0.06). The relative risk increased with follow-up duration, progressing to 2.0 after 15 years (13/6.6, P = 0.01). The excess risk after 10 years was not due simply to prolonged estrogen use, since there was no clear dose-response relation to accumulated years of use. However, higher risk accrued to women using higher-dose tablets and those taking the medication on an other than daily basis. In addition, after 10 years of follow-up observation, two factors related to low risk of breast cancer, multiparity and oophorectomy, were no longer so related. Finally, estrogen use was related to an especially high risk of breast cancer among women in whom benign disease developed after they had started the drug.
D000368:Aged; D001941:Breast Diseases / Q000150:complications; D001943:Breast Neoplasms / Q000453:epidemiology*; D002369:Castration; D004305:Dose-Response Relationship, Drug; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007629:Kentucky; D008593:Menopause; D008875:Middle Aged; D010298:Parity; D012306:Risk; D013997:Time Factors
D004966:Estrogens, Conjugated (USP)